Eric I. Richman

Chief Executive Officer & Director

  • Grey LinkedIn Icon

Mr. Richman has over 25 years of experience in the biotechnology and pharmaceutical industry as an investor and in operating roles. He previously served as a Venture Partner at Brace Pharma Capital, a life science venture capital firm and served as Chief Executive Officer of Tyrogenex Inc., a biopharmaceutical company and Chief Executive Officer of PharmAthene, Inc. subsequently acquired by Altimmune, Inc. He previously held various commercial and strategic positions at MedImmune, Inc. over a 12-year period from its inception. Mr. Richman currently serves as a director of Neubase Therapeutics, Inc. (Nasdaq: NBSE), NovelStem International Corp. (OTCMKTS: NSTM), and co-founder and director of InFuse Holdings and LabConnect, Inc. where he serves as the Chairman of the Board. He previously served on a number of Boards including Adma Biologics, Inc. (Nasdaq: ADMA), Zyversa Therapeutics, Inc., LEV Pharma (OTC: LEVP) (acq. by Viropharma), among others. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a M.B.A. from the American Graduate School of International Management. 

Manolo Bellotto, PhD

General Manager & President

  • Grey LinkedIn Icon

Dr. Bellotto has an international pharmaceutical experiencing encompassing product, medical and advocacy development, commercialization and international research collaborations in major and rare/orphan disease indications across various continents. He worked and consulted for small, medium and large pharma and biopharma companies, including Helsinn, ESMO, GSK, Novartis, Abbott, Teva and Pfizer. He holds a Ph.D. in Molecular Developmental Genetics from the University of Zurich after having studied at the Biocentre of the University of Basel and at the Fredrich Miescher Institute for Biomedical Research in Basel.

Xavier Barril, PhD

Chief Scientific Officer

  • Grey LinkedIn Icon

Dr. Barril is a recognised expert in the field of computational chemistry and drug discovery. Prior to his incorporation to the University of Barcelona as ICREA professor, he developed his career at Vernalis (Cambridge, UK) as Senior Investigator. Among other discoveries, Xavier is co-inventor of the Hsp90 inhibitors that Vernalis licensed to Novartis and which underwent clinical trials. Xavier has co-authored more than 80 scientific publications and 10 patents. He is the inventor of the innovative platform technology that Gain Therapeutics is exploiting to identify new structurally targeted allosteric regulators. He holds a Ph.D. in Biochemistry from the University of Barcelona.

Salvatore Calabrese

Chief Financial Officer

  • Grey LinkedIn Icon

Mr. Calabrese has an extensive international experience in public companies and in the biopharmaceutical sector. He started his career at PwC in Milano and then in Boston, where he served several companies listed on NASDAQ and NYSE. Subsequently .he joined Novuspharma S.p.A, a subsidiary of Cell Therapeutics, Inc. (NASDAQ: CTIC), as Accounting & Finance Manager. From 2005 to 2014 he worked at Gentium S.p.A. (NASDAQ: GENT) covering various roles including Senior Vice President, CFO and COO. Following the acquisition of Gentium by Jazz Pharmaceuticals (NASDAQ: JAZZ), he worked as General Manager and Site Leader for the Italian Operation. He is currently CFO and Officer Responsible for the preparation of corporate financial reports of Molmed SpA (MLMD.MI). He holds a master’s Degree in Accounting, Audit and Financial Control from the University of Pavia and a bachelor’s Degree in Economics from the University of Messina. He is listed in the Italian National Audit Register held by the National Justice Department.

Ana Maria Garcia Collazo, PhD

Head of Research

Natàlia Pérez Carmona, PhD

Head of Biology

Elena Cubero, PhD

Head of Computational Modelling

Roberto Maj, PharmD

Head of Development

  • Grey LinkedIn Icon

Dr. Maj has over 30 years of experience in pharma and biotech managing small molecule development. He previously headed drug development at Inositec, Telormedix (which he co-founded), and was also Head of Preclinical Development at Newron Pharmaceuticals, mondoBIOTECH and Brane Discovery. Roberto started his career as a senior researcher in the CNS department at Pharmacia & Upjohn where he leaded the neuropharmacology lab. He holds a Pharmacy degree from the University of Milan.

  • Grey LinkedIn Icon

Dr. Garcia-Collazo is a senior medicinal chemist with nearly 20 years of experience in directing research groups through the drug discovery process. Her career started at Karo Bio (Sweden). She returned to Spain after 8 years to be part of the newly created drug discovery unit of the Spanish National Institute for Cancer Research (CNIO, Madrid). She then joined Minoryx (Barcelona) where, as Head of Medicinal Chemistry and Process Chemistry, contributed to the development of the clinical candidate MIN-102 for potential use in X-ALD treatment. Ana has co-authored more than 40 scientific publications and patents. She holds a Ph.D. in Organic Chemistry from Santiago de Compostela University and was a post-doctoral Marie Curie Research Fellow in the group of the Nobel Prize winner Prof. Jean-Marie Lehn at Université Louis Pasteur (France).

  • Grey LinkedIn Icon

Dr. Cubero has over 18 years of experience in the field of computational chemistry and drug discovery in public institutions, pharma and biotech companies. She has developed her career at the Institute for Research in Biomedicine (IRB Barcelona-PCB, Spain), Esteve (Barcelona, Spain) and Minoryx, (Barcelona, Spain) as head of computer-aided drug design department (CADD) and as a project leader of preclinical-stage programs. Elena has co-authored more than 35 publications, including journals, books, reviews and patents. She holds a Ph.D. in Chemistry from Universitat de Barcelona.

  • Grey LinkedIn Icon

Dr. Pérez-Carmona acquired her experience in the drug discovery process in pharma and biotech companies. Her first contact with the pharmaceutical industry was in the Autoimmunity Department of Almirall Laboratories. She then joined the Biology Department in the biotech company Minoryx Therapeutics, focused on rare diseases, where she held the position of Research Scientist and Biology Project Leader. She had previously been working as an intern at the The Royal Veterinary College in London and at the Hannover Medical School. She has co-authored several peer-reviewed publications and has presented her work at scientific conferences both as oral presentations and posters. She holds a master’s degree and a Ph.D. in Biomedicine from the University of Barcelona.


Gain Therapeutics, Inc.

Follow us

  • LinkedIn Social Icon